{
  "ticker": "DXB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972574",
  "id": "02972574",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250725",
  "time": "0835",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m436829nbkck.pdf",
  "summary": "### **Material Information Summary (Quarterly Report \u2013 Appendix 4C)**  \n\n#### **Operational & Financial Highlights**  \n- **License agreement with Amicus Therapeutics for DMX-200**:  \n  - Potential total value: **~AU$940m** (US$590m) in milestones + **low-teen to low-20s royalties** on net sales.  \n  - **Upfront payment received**: **AU$48m** (US$30m) in May 2025.  \n- **Additional licensing deals** (Advanz Pharma, Taiba, Fuso): **Total potential milestones ~AU$1.4bn**, with **AU$65m received to date**.  \n  - **Fuso milestone payment**: **AU$4.2m** (before tax) for ACTION3 trial site activation in Japan.  \n- **FDA confirmation**: **Proteinuria accepted as primary endpoint** for US approval of DMX-200 in FSGS.  \n- **ACTION3 Phase 3 trial progress**:  \n  - **219 patients randomized/dosed** (as of 24 July 2025).  \n  - **6th successful IDMC review** completed.  \n- **Cash position**: **AU$68.3m** at 30 June 2025 (vs. **AU$17.0m** at 31 March 2025).  \n- **Net operating cash inflow**: **AU$45.6m** (driven by licensing payments and option exercises).  \n\n#### **Key Cash Flow Items**  \n- **Cash inflow**:  \n  - **Licensing payments (Amicus + Fuso)**: **~AU$52.2m**.  \n  - **Option exercises**: **AU$6.0m**.  \n- **R&D spend**: **AU$4.7m** (quarter), **AU$22.4m** (YTD).  \n\n### **No Material Capital Raisings or Trading Halts Identified**",
  "usage": {
    "prompt_tokens": 6310,
    "completion_tokens": 409,
    "total_tokens": 6719,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T22:58:15.270292"
}